Opinion

Is the industry’s VAWD accreditation being used for unfair advantage?

Five commercial trends to watch in 2017

Resources for education about senior citizens and long-term care

Do you need to hire a hub service for your Patient Access Strategy or can you get by with a good specialty pharmacy

Morris & Dickson publishes a family and company history

Ten payer pressures to act on now

The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand

Dispense As Written

Sharing clinical data—EvGen—will improve both drug development and health outcomes analysis

A new, market-driven model of drug development and commercialization is appearing*

Looking at 'cost' and 'value' under different evaluation processes

Looking at the essential value of well-managed supply chains

HDMA seeks to encourage more outreach to business partners and government

Despite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay

A Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets

Fees paid to FDA by small generic manufacturers are financially 'unfair'